Healthcare Economics
Pfizer’s $100 Billion Gamble: Inside the High-Stakes Battle for the Weight-Loss Drug Crown
Pfizer is playing hardball in the $100B weight-loss drug market, betting its future on a pill to challenge the injectable giants, Novo Nordisk and Eli Lilly.
The Rybelsus Revelation: Why One Chart Correction Unlocks Novo Nordisk’s True Value
A minor chart correction for Novo Nordisk reveals a major lesson in financial analysis, highlighting the crucial difference between its diabetes and obesity drugs.
The Ozempic Economy: How a Weight-Loss Shot is Reshaping Markets and Killing the Business Lunch
A new class of weight-loss drugs is shaking up the economy, impacting the stock market and threatening the future of the traditional business lunch.
The Price of a Puppy: Why the UK’s Vet Industry Is a Crucial Case Study in Market Economics and Investing
The UK’s vet industry is a case study in market economics, revealing how consolidation and opacity impact prices, inviting regulatory scrutiny.
The $600M Bet: How the Global Race for Weight-Loss Drugs is Rewriting the Rules of Biotech Investing and Tapping into China’s R&D Power
A US biotech’s $600M raise for weight-loss drugs reveals a key strategy: using China for faster, cheaper clinical trials, altering biotech investing.